Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update to Rociletinib Data with the RECIST Confirmed Response Rate.

× No keyword cloud information.

28 in total

1. Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).

Authors: Daria Gaut; Myung Shin Sim; Yuguang Yue; Brian R Wolf; Phillip A Abarca; James M Carroll; Jonathan W Goldman; Edward B Garon
Journal: Clin Lung Cancer Date: 2017-06-20 Impact factor: 4.785

Review 2. Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Authors: Salvatore Corallo; Ettore D'Argento; Antonia Strippoli; Michele Basso; Santa Monterisi; Sabrina Rossi; Alessandra Cassano; Carlo M Barone
Journal: Target Oncol Date: 2017-04 Impact factor: 4.493

Review 3. Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors: Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal: Target Oncol Date: 2018-04 Impact factor: 4.493

Review 4. Current chemotherapeutic regimens for brain metastases treatment.

Authors: Joo Yeon Nam; Barbara J O'Brien
Journal: Clin Exp Metastasis Date: 2017-09-16 Impact factor: 5.150

Review 5. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Authors: Rashmi R Shah
Journal: Drug Saf Date: 2017-03 Impact factor: 5.606

Review 6. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Authors: G M O'Kane; T A Barnes; N B Leighl
Journal: Curr Oncol Date: 2018-06-13 Impact factor: 3.677

Review 7. Targeting EGFR in Lung Cancer: Current Standards and Developments.

Authors: Asunción Díaz-Serrano; Pablo Gella; Elisabeth Jiménez; Jon Zugazagoitia; Luis Paz-Ares Rodríguez
Journal: Drugs Date: 2018-06 Impact factor: 9.546

8. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.

Authors: Xu Zhang; Tapan K Maity; Karen E Ross; Yue Qi; Constance M Cultraro; Meriam Bahta; Stephanie Pitts; Meghana Keswani; Shaojian Gao; Khoa Dang P Nguyen; Julie Cowart; Fatos Kirkali; Cathy Wu; Udayan Guha
Journal: Cancer Res Date: 2021-03-16 Impact factor: 13.312

Review 9. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.

Authors: Yoshihisa Kobayashi; Tetsuya Mitsudomi
Journal: Cancer Sci Date: 2016-08-09 Impact factor: 6.716

Review 10. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Authors: Nele Van Der Steen; Chiara Caparello; Christian Rolfo; Patrick Pauwels; Godefridus J Peters; Elisa Giovannetti
Journal: Onco Targets Ther Date: 2016-10-06 Impact factor: 4.147